Who
Barry E. Greene
Director
Company insider
Files Form 4 as: Director, City Therapeutics; Director, Dyne Therapeutics; Director, Karyopharm Therapeutics; President and CEO, Sage Therapeutics; Director, Acorda Therapeutics; President, Alnylam Pharmaceuticals; Director and 10% owner, Regulus Therapeutics.
In numbers
- Trades disclosed
- 300
- Buys
- 9
- Sells
- 23
- Bought
- $2.1M
- Sold
- $61.3M
- Companies
- 7
- Companies where not an officer
- 5
- First trade
- 31 Oct 2006
- Last trade
- 15 Oct 2026
- Last filed
- 19 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Oct 2026filed 19 Oct 2026 | CTY City Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,649 at $0.00 | filing |
| 22 Jun 2026filed 23 Jun 2026 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —57,463 at $0.00 | filing |
| 22 Jun 2026filed 23 Jun 2026 | DYN Dyne Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —57,463 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —15,508 at $0.00 | filing |
| 21 May 2026filed 26 May 2026 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —15,508 at $0.00 | filing |
| 31 Jul 2025filed 31 Jul 2025 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code D | —174,000 | filing |
| 31 Jul 2025filed 31 Jul 2025 | Sage Therapeutics | SEC FORM 4 Code U | —46,940 | filing |
| 31 Jul 2025filed 31 Jul 2025 | Sage Therapeutics | SEC FORM 4 Code D | —53,229 | filing |
| 28 May 2025filed 29 May 2025 | KPTI Karyopharm Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —4,600 at $0.00 | filing |
| 10 Apr 2025filed 11 Apr 2025 | Sage Therapeutics | SEC FORM 4 Code A | —19,964 at $0.00 | filing |
| 10 Apr 2025filed 11 Apr 2025 | Sage Therapeutics | SEC FORM 4 Code F | $34K4,862 at $6.91 | filing |
| 16 Jan 2025filed 21 Jan 2025 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code A | —174,000 at $0.00 | filing |
| 5 Aug 2024filed 7 Aug 2024 | Sage Therapeutics | SEC FORM 4 Code A | —50,400 at $0.00 | filing |
| 5 Aug 2024filed 7 Aug 2024 | Sage Therapeutics | SEC FORM 4 Code F | $110K12,273 at $8.96 | filing |
| 29 May 2024filed 30 May 2024 | KPTI Karyopharm Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —69,000 at $0.00 | filing |
| 13 Feb 2024filed 15 Feb 2024 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code A | —168,000 at $0.00 | filing |
| 4 Aug 2023filed 8 Aug 2023 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code A | —195,000 at $0.00 | filing |
| 24 May 2023filed 25 May 2023 | KPTI Karyopharm Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —34,000 at $0.00 | filing |
| 13 Feb 2023filed 15 Feb 2023 | Sage Therapeuticsoption or derivative | SEC FORM 4 Code A | —66,500 at $0.00 | filing |
| 10 Nov 2022filed 15 Nov 2022 | Sage Therapeutics | SEC FORM 4 Bought | $500K14,500 at $34.48 | filing |
News
Alnylam Pharmaceuticals (NASDAQ:ALNY) and TScan Therapeutics (NASDAQ:TCRX) Critical SurveyALNY · themarketsdaily.com · 20 Oct 2026Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Gets Price Target Reduction from Wells Fargo & CompanyALNY · tickerreport.com · 17 Oct 2026Oncocyte (NASDAQ:IMDX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) Critical SurveyALNY · tickerreport.com · 14 Oct 2026
0 headlines in the last 90 days name Barry E. Greene; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.